(Q48092928)

English

Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs

scientific article published on 4 February 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/23381882

Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/23381882

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Ichiro Ieiri

1

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/23381882

Shyohei Tsunemitsu

2

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/23381882

Kazuya Maeda

3

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/23381882

Yukie Ando

4

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/23381882

Noritomo Izumi

5

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/23381882

Miyuki Kimura

6

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/23381882

Naoe Yamane

7

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/23381882

Tsuyoshi Okuzono

8

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/23381882

Mariko Morishita

9

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/23381882

Naoki Kotani

10

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/23381882

Eri Kanda

11

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/23381882

Mariko Deguchi

12

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/23381882

Kyoko Matsuguma

13

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/23381882

Shunji Matsuki

14

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/23381882

Takeshi Hirota

15

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/23381882

Shin Irie

16

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/23381882

Hiroyuki Kusuhara

17

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/23381882

Yuichi Sugiyama

18

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/23381882

publication date

4 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/23381882

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/23381882

53

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/23381882

6

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/23381882

654-661

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/23381882

Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.62

21 January 2018

Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.62

21 January 2018

Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.62

21 January 2018

Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.62

21 January 2018

Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.62

21 January 2018

Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.62

21 January 2018

Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.62

21 January 2018

Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.62

21 January 2018

Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.62

21 January 2018

Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.62

21 January 2018

Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.62

21 January 2018

Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.62

21 January 2018

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.62

21 January 2018

Transporter-mediated drug--drug interactions involving OATP substrates: predictions based on in vitro inhibition studies.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.62

21 January 2018

Novel strategies for microdose studies using non-radiolabeled compounds

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.62

21 January 2018

Impact of microdosing clinical study -- why necessary and how useful?

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.62

21 January 2018

4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.62

21 January 2018

Sex-related differences in pharmacokinetics and pharmacodynamics of anti-hypertensive drugs

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.62

21 January 2018

First-pass metabolism of midazolam by the human intestine.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.62

21 January 2018

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.62

21 January 2018

Predicting drug candidate victims of drug-drug interactions, using microdosing

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.62

21 January 2018

Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.62

21 January 2018

Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.62

21 January 2018

Differential roles of P-glycoprotein, multidrug resistance-associated protein 2, and CYP3A on saquinavir oral absorption in Sprague-Dawley rats

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.62

21 January 2018

Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.62

21 January 2018

Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.62

21 January 2018

Identifiers

10.1002/JCPH.62

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/23381882

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/23381882

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48092928&oldid=2184500472"